Lucia Zisser
Vienna, 1090, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Feasibility of [68Ga]Ga-FAPI PET Molecular Imaging in Atherosclerosis Compared with [18F]FDG in Oncological Patients.
Journal: Diagnostics (Basel, Switzerland)
Published: October 17, 2025
Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [18F]FDG PET/CT.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 28, 2025
Extracellular Vesicles as Mediators in Atherosclerotic Cardiovascular Disease.
Journal: Journal of lipid and atherosclerosis
Published: March 29, 2024
Induction of Arterial Inflammation by Immune Checkpoint Inhibitor Therapy in Lung Cancer Patients as Measured by 2-[18F]FDG Positron Emission Tomography/Computed Tomography Depends on Pre-Existing Vascular Inflammation.
Journal: Life (Basel, Switzerland)
Published: December 19, 2023
Panel Comparative Analysis Tool: An Open-Source Comparative Analysis Tool for Next-Generation Sequencing Panel Target Regions.
Journal: The Journal of molecular diagnostics : JMD
Published: June 20, 2023
Full-length target sequences of GeoMx digital spatial profiling probes reveal that gene-promiscuity predicts probe sensitivity to EDTA tissue decalcification.
Journal: Scientific reports
Published: June 08, 2023
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 06, 2023
Update on classification of oncocytic neoplasms of the kidney.
Journal: Current opinion in urology
Published: January 20, 2023
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Journal: Nuclear medicine communications
Published: September 19, 2022
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: September 01, 2021
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Cancers
Published: April 28, 2021
Last Updated: 09/26/2026